2026-05-05T04:59:13Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/sjggt.000025 2026-03-17 PTZ.SJGGT:VOL12

Pembrolizumab in Combination with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Clinical Evidence, Regulatory Approval and Therapeutic Implications Sulaiman Naseer<p><strong>Background: </strong>Primary peritoneal carcinoma, fallopian tube cancer, and platinum-resistant epithelial ovarian cancer are aggressive cancers with few treatment choices and a dismal prognosis. In a variety of solid malignancies, immune checkpoint medications that target the programmed death receptor-1 (PD-1) have demonstrated encouraging activity.</p><p><strong>Objectives:</strong> To examine the clinical effectiveness, safety, and therapeutic implications of pembrolizumab in combination with paclitaxel, with or without bevacizumab, for platinum-resistant ovarian cancers that express programmed death-ligand 1 (PD-L1). This approval was recently made by the US Food and Drug Administration (FDA).</p><p><strong>Methods: </strong>Reviewed KEYNOTE-B96 (NCT05116189) clinical trial data, prescription information, and regulatory announcements. Progress-free survival (PFS) and overall survival (OS), as determined by the RECIST v1.1 criteria, were key effectiveness goals.</p><p><strong>Results: </strong>PFS was 8.3 months in the pembrolizumab arm and 7.2 months in the placebo arm for patients with PD-L1 combination positive score (CPS) ≥1 (HR 0.72; p = 0.0014). 18.2 months and 14.0 months, respectively, were the median OS (HR 0.76; p = 0.0053). The safety profile aligned with immune-related side effects linked to PD-1 inhibitors that have been documented before.</p><p><strong>Conclusion:</strong> The treatment of platinum-resistant ovarian tumors has advanced clinically with the approval of pembrolizumab in combination therapy. PD-L1 CPS-based biomarker-driven patient selection improves precision oncology methods and could lead to better survival rates in this high-risk group.</p> Scientific Journal of Genetics and Gene Therapy - Peertechz Publications 2026-03-17 Research Article https://doi.org/10.17352/sjggt.000025 en Copyright © Sulaiman Naseer et al.